Prescient Therapeutic (PTX) is a clinical stage oncology company currently engaged in the development of novel products for the treatment of cancer. Prescient Therapeutics (formerly Virax Holdings) (ASX:PTX) is a biopharma company, focused in discovery and development of immunotherapeutic products for the treatment of chronic infectious diseases and cancer.
Prescient Therapeutics Limited
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”PTX.AX” api=”yf” style=”font-size: 15px”]
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/prescient-therapeutics” connections=”true” suffix=””]
Prescient has two discovery platforms- 1) Co-X-Gene_ technology enabling co-expression of antigens and cytokines in DNA vaccines so as to manipulate the immune system in the appropriate fashion to treat disease. 2) FPV delivery technology consists of Fowlpox Virus (FPV) as the delivery vehicle.